Clinical Trial Update: Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daratumumab therapy in patients with refractory or relapsed amyloidosis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: University Hospital, Limoges | Conditions: Amyloidosis | Phase 2 | Status: COMPLETED